HSA
PHAT icon

Hussman Strategic Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Hussman Strategic Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84,000
Closed -$933K – 301
2026
Q1 		$933K Sell
84,000
-63,000
-43% -$796K 0.2% 201
2025
Q4 		$2.44M Buy
+147,000
New +$2.1M 0.59% 59

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Hussman Strategic Advisors's PHAT Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 84,000 shares — an estimated $933K sold.

Hussman Strategic Advisors first reported a position in PHAT in Q4 2025 and held it in 2 quarters. The position peaked at $2.44M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 84,000 Phathom Pharmaceuticals shares in Q2 2026, an estimated $933K.
  • Hussman Strategic Advisors first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Hussman Strategic Advisors's Phathom Pharmaceuticals position peaked at $2.44M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.